Reports on Herg Screening Market

July 20th 2016 Mumbai, India: Bharatbook.com announces a report on “Reports on hERG Screening Market". hERG Screening has its major role in the pharmaceutical field in drug release process. Some drugs may prolong the QT interval in normal and healthy individuals and result in QT Syndrome.

This report gives an insight into the hERG Screening market and its impact on drug development and discovery. The study provides global market analysis for hERG Screening for sensitivity of potassium ion channels towards drugs. Business profiles of 31 major companies are discussed in the report. The report serves as a guide to global hERG Screening market, as it covers more than 190 companies that are engaged in hERG Screening R&D, discovery, testing and supply of products and services. Major Contract Research Organizations and Universities serving the market are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

Human Ether-a-go-go Related Gene (hERG gene) (KCNH2) is an encoder of the potassium ion channel that repolarizes IKr current in the heart. It consists of 6 transmembrane domains which are serially numbered from S1-S6. The abnormalities resulting in this channel can either lead to Long QT syndrome (LQT2) or Short QTsyndrome causing loss of function mutations and gain of function mutations respectively. Both of these are considered as potentially fatal cardiac arrhythmia caused due to repolarisation disturbances of the cardiac action potential. hERG Screening has its major role in the pharmaceutical field in drug release process. Some drugs may prolong the QT interval in normal and healthy individuals and result in QT Syndrome. This side effect has promoted majority of pharmaceutical companies to screen compounds for hERG channel activity in early stages of drug discovery and development process....